Apeloa subsidiary secures approval for flu treatment

Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd., a subsidiary of Apeloa Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for oseltamivir phosphate for oral suspension. This approval, categorized as a Class 3 chemical drug, covers the treatment and prevention of influenza A and B in patients aged two weeks and above, and one year and above, respectively.

The active metabolite of oseltamivir phosphate, oseltamivir carboxylate, acts as a selective influenza virus neuraminidase inhibitor, preventing the spread of the virus. The company's total research and development investment for this product stands at RMB 8,378,900.

The approval is expected to enhance Apeloa Pharmaceutical's market competitiveness and broaden its product offerings. The Chinese market for oseltamivir phosphate for oral suspension was approximately 5 million bottles in 2024, with sales reaching RMB 160 million. However, the company noted that the production and sales of pharmaceuticals could be affected by policy, regulatory changes, and market conditions.